Indivior PLC (INDV)
NASDAQ: INDV · Real-Time Price · USD
13.93
+0.27 (1.98%)
Jun 12, 2025, 4:00 PM - Market closed
Indivior Revenue
Indivior had revenue of $266.00M in the quarter ending March 31, 2025, a decrease of -6.34%. This brings the company's revenue in the last twelve months to $1.17B, up 4.09% year-over-year. In the year 2024, Indivior had annual revenue of $1.19B with 8.69% growth.
Revenue (ttm)
$1.17B
Revenue Growth
+4.09%
P/S Ratio
1.46
Revenue / Employee
$1,113,225
Employees
1,051
Market Cap
1.71B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.19B | 95.00M | 8.69% |
Dec 31, 2023 | 1.09B | 192.00M | 21.31% |
Dec 31, 2022 | 901.00M | 110.00M | 13.91% |
Dec 31, 2021 | 791.00M | 144.00M | 22.26% |
Dec 31, 2020 | 647.00M | -138.00M | -17.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
INDV News
- 10 days ago - Indivior to delist from London Stock Exchange, maintain Nasdaq listing - Reuters
- 10 days ago - Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained - PRNewsWire
- 16 days ago - Indivior Announces Patrick Barry as Chief Commercial Officer - PRNewsWire
- 4 weeks ago - Indivior to Participate in Upcoming Investor Events - PRNewsWire
- 6 weeks ago - New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy - PRNewsWire
- 6 weeks ago - Indivior: Trying To Break Addiction - Seeking Alpha
- 7 weeks ago - Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 7 weeks ago - Indivior Announces Q1 2025 Financial Results - PRNewsWire